SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 12.71% to Rs. 13544.20 millions for the quarter ended September 2022 as compared to Rs. 12017.10 millions during the corresponding quarter last year.Net profit showed a marginal rise at Rs. 1464.40 millions for the quarter ended September 2022, as compared to corresponding quarter of last year.The company reported a good operating profit of 2457.60 millions compared to 2352.20 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 13544.20 12017.10 12.71 25147.50 24714.00 1.75 49966.00 50514.40 -1.09
Other Income 4.60 196.10 -97.65 10.80 237.70 -95.46 499.80 835.20 -40.16
PBIDT 2457.60 2352.20 4.48 3730.10 5139.30 -27.42 11044.30 15819.70 -30.19
Interest 119.60 45.10 165.19 206.60 65.40 215.90 166.70 127.70 30.54
PBDT 2338.00 2307.10 1.34 3523.50 5073.90 -30.56 10877.60 15692.00 -30.68
Depreciation 668.00 542.20 23.20 1128.90 977.10 15.54 1793.10 1526.00 17.50
PBT 1670.00 1764.90 -5.38 2394.60 4096.80 -41.55 9084.50 14166.00 -35.87
TAX 205.60 333.60 -38.37 205.60 738.60 -72.16 1144.50 2412.10 -52.55
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 1464.40 1431.30 2.31 2189.00 3358.20 -34.82 7940.00 11753.90 -32.45
Equity 393.10 393.10 0.00 393.10 393.10 0.00 393.10 393.10 0.00
PBIDTM(%) 18.15 19.57 -7.30 14.83 20.80 -28.67 22.10 31.32 -29.42

Alembic Pharma Share Price

785.40 8.05 (1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×